Nuformix (LON:NFX) Trading 17.6% Higher – Still a Buy?

Nuformix plc (LON:NFX)’s share price traded up 17.6% during trading on Tuesday . The company traded as high as GBX 0.30 and last traded at GBX 0.30. 29,456,109 shares traded hands during mid-day trading, a decline of 23% from the average session volume of 38,018,152 shares. The stock had previously closed at GBX 0.26.

Nuformix Price Performance

The company has a 50-day moving average of GBX 0.26 and a two-hundred day moving average of GBX 0.23. The company has a market capitalization of £6.33 million, a PE ratio of -7.63 and a beta of 1.22.

Nuformix (LON:NFX) last posted its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) EPS for the quarter.

About Nuformix

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.